OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Article

September 21, 2022

Alpelisib Displays Clinical Benefit in Pediatric PIK3CA-Related Overgrowth Spectrum Disease

Author(s):

Caroline Seymour
Conference|ESMO Congress

Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.

Guillaume Canaud, MD, PhD

Guillaume Canaud, MD, PhD

Alpelisib (Piqray) decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum (PROS) disease who received treatment with the PI3K inhibitor under compassionate use, according to findings from the prespecified secondary end point of the retrospective EPIK-P1 study (NCT04285723) presented at the 2022 ESMO Congress.

The findings showed that lipomatosis, scoliosis, hypertrophy, inflammation, and developmental delays occurred in at least 20% of pediatric patients at the index date and were improved as early as 12 weeks. Notably, the improvement in performance status score at 24 weeks was seen in 24.2% of pediatric patients, and no patients required surgery because of disease progression during this period vs 84.6% (n = 33/39) of those who underwent at least 1 surgery (range, 1-15) between diagnosis and the pre-index period.

“In the EPIK-P1 study, a clinically meaningful proportion of pediatric patients attained response,” lead study author Guillaume Canaud, MD, PhD, and coauthors wrote in the poster. “The majority of the patients had any reduction in the sum of their target lesion volume and none of the patients had radiologically confirmed disease progression during the study period.”

Alpelisib is an oral, alpha-selective, PI3K inhibitor that received an accelerated approval from the FDA on April 6, 2022, for the treatment of adult and pediatric patients at least 2 years of age with severe manifestations of PROS who require systemic therapy. The agent has shown clinical benefit and an acceptable safety profile in prior studies performed in this population.

In primary findings from EPIK-P1, 37.5% of complete cases (n = 12/32) showed at least a 20% reduction in target lesion volume after 24 weeks.

EPIK-P1 was a retrospective, noninterventional chart review of patients at least 2 years of age with PROS experiencing severe or life-threatening conditions.

To be eligible for inclusion, patients had to receive at least 1 dose of alpelisib on or before September 23, 2019 and have relevant evaluations on or before the cut-off date of March 9, 2020.

The entire study population (n = 57) was used for all efficacy and safety analyses apart from the primary end point, which evaluated only the patients without a missing response assessment (n = 32).

The primary end point was the proportion of patients with at least a 20% reduction from the index date in the sum of measurable target lesion volume at week 24. Secondary end points included treatment effect on performance status, frequency of PROS-related surgeries, changes in signs/symptoms over time, and safety.

Of the total patient population, 39 were pediatric patients who had a median age of 10 years (range, 2-17). The overall median patient age was 14.0 years (range, 2-50). Most patients in both populations had congenital overgrowth as opposed to early childhood-onset overgrowth, mosaic distribution vs sporadic occurrence, and CLOVES subtype compared with MCAP/MCM, KTS, FIL, or other.

Pediatric patients received a median dose of alpelisib of 50.0 mg per day (range, 50.0-250.0).

Regarding safety, 79.5% (n = 31) of pediatric patients experienced at least 1 adverse effect (AE); treatment-related AEs (TRAEs) occurred in 23.1% (n = 9) of pediatric patients.

The most common any-grade AEs were diarrhea (n = 5; 12.8%), vascular malformation (n = 4; 10.3%), stomatitis (n = 3; 7.7%), aphthous ulcers (n = 3; 7.7%), inflammation (n = 3; 7.7%), hypoglycemia (n = 3; 7.7%), hyperglycemia (n = 2; 5.1%), disseminated intravascular coagulation (n = 2; 5.1%), and gait disturbance (n = 2; 5.1%). Grade 3/4 AEs included cellulitis, adrenal insufficiency, dyspnea, and wound infection (n = 1; 2.6% each).

The most frequent TRAEs were aphthous ulcer, stomatitis (n = 3; 7.7% each), and hyperglycemia (n = 2; 5.1%).

The most common serious AEs in pediatric patients were gait disturbances (n = 2; 5.1%) and vascular malformations (n = 2; 5.1%), neither of which was determined to be treatment related.

No AE led to treatment discontinuation, although 2 patients (5.1%) required dose interruptions because of AEs. No deaths occurred during the study.

“Treatment with alpelisib allowed [patients] to avoid PROS-related surgeries and resulted in improvement of performance status [and] PROS-related signs and symptoms,” the study authors wrote. “In addition to the previously reported lesion volume reduction and well tolerated safety profile, these real-world data [show] a meaningful clinical benefit with alpelisib in pediatric patients with PROS.”

The confirmatory EPIK-P2 trial (NCT04589650) is recruiting patients to further assess the efficacy, safety, and pharmacokinetics of alpelisib in pediatric and adult patients with PROS.

Reference

Canaud G, Irvine A, Ankrah N, et al. Clinical benefit of alpelisib in pediatric patients with PIK3CA-related overgrowth spectrum (PROS): an EPIK-P1 analysis. Ann Oncol. 2022;33(suppl 7):S755. doi:10.1016/annonc.2022.07.597

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Related Content
Advertisement
Non–Small Cell Lung Cancer |  Image by Ashling Wahner &  MJH Life Sciences Using AI
June 13th 2025

TT125-802 Demonstrates Potential in Advanced NSCLC and Solid Tumors

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Older NMP1-Mutant/KMT2A-Rearranged AML |   Image Credit: © Oleksandr - stock.adobe.com
June 12th 2025

Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NMP1/KMT2A-Altered AML

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
November 18th 2021

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

The FDA has approved taletrectinib for use in patients with ROS1-positive advanced non–small cell lung cancer.
June 11th 2025

FDA Approves Taletrectinib for ROS1+ Advanced NSCLC

High-Grade Glioma | Image Credit: © alexlmx - stock.adobe.com
June 11th 2025

Iopofosine I-131 Demonstrates Safety and Early Efficacy in Pediatric R/R High-Grade Glioma

Related Content
Advertisement
Non–Small Cell Lung Cancer |  Image by Ashling Wahner &  MJH Life Sciences Using AI
June 13th 2025

TT125-802 Demonstrates Potential in Advanced NSCLC and Solid Tumors

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Older NMP1-Mutant/KMT2A-Rearranged AML |   Image Credit: © Oleksandr - stock.adobe.com
June 12th 2025

Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NMP1/KMT2A-Altered AML

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
November 18th 2021

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

The FDA has approved taletrectinib for use in patients with ROS1-positive advanced non–small cell lung cancer.
June 11th 2025

FDA Approves Taletrectinib for ROS1+ Advanced NSCLC

High-Grade Glioma | Image Credit: © alexlmx - stock.adobe.com
June 11th 2025

Iopofosine I-131 Demonstrates Safety and Early Efficacy in Pediatric R/R High-Grade Glioma

Latest Conference Coverage

Dr Fathi on the Efficacy and Safety of Ziftomenib in R/R NPM1-Mutant AML

Dr Schetelig on Haploidentical vs Mismatched Transplant Efficacy in AML/ALL/MDS

Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell Lymphoma

Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact